Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months
Analysts see break-up as an effort to unlock value for proprietary pharmaceuticals unit, where expectations of slowing Humira sales may have left the company undervalued.
Analysts see break-up as an effort to unlock value for proprietary pharmaceuticals unit, where expectations of slowing Humira sales may have left the company undervalued.